Board Disclosures

The leadership of Bladder Cancer has disclosed the following information in keeping with the journal's disclosure policy.

Seth P. Lerner, MD, Editor-in-Chief
Advisory Board (with honoraria): BioCancell, miR Scientific, QED Therapeutics, UroGen
Clinical Trials: Endo, FKD, JBL (SWOG), Roche/Genentech (SWOG), Viventia
Consultant (with honoraria): BioCancell, UroGen, Vaxiion
Honoraria: BioCancell, miR Scientific, QED Therapeutics, UroGen, MSD Korea (speaker honoraria)
Patent Pending: TCGA subtypes single patient classifier (the Broad Institute)
Other: IOS Press (editorial responsibilities, compensated)

Dan Theodorescu, MD, PhD, Editor-in-Chief
Consultant: Machavert, Merck, Urogen
Honoraria: Machavert, Merck, Urogen
Licenses/Patents: University of Colorado
Research Support: Medivation/Astellas
Stockholder in: Aurora Oncology, PrecisionProfile
Other: IOS Press (editorial responsibilities, compensated)

Cora N. Sternberg, MD, Associate Editor
Honoraria: Pfizer, IPSEN
Consultant: Eisai, Pfizer, IPSEN, BMS, Roche, Bayer, MSD, Novartis

Consultant: Merck, Clovis, BMS, Incyte, AstraZeneca
Honoraria: Lilly
Institutional Funding: Janssen

Consultant: Sanofi, Bayer, Pfizer
Honoraria: Clovis, Janssen, AstraZeneca, Sanofi, Astellas
Institutional Funding: Roche-Genentech, Bayer, Sanofi , Janssen, Medivation, Exelixis, Sanofi Genzyme

Piyush K. Agarwal, MD, Associate Editor
Advisory Board (unpaid): AstraZeneca

Joaquim Bellmunt, MD, PhD, Associate Editor
Personal financial interests:
Advisory board & lecture fee: Genentech, Pfizer, BMS, AstraZeneca
Institutional financial interests:
Advisory board & lecture fee: Merck, Pierre-Fabre
Trial Sponsorship through APRO: KEYNOTE 045 trial (Merck), TAK-128 project in Bladder (Takeda), Avelumab Carbo in prostate (Pfizer/MSD)
Stocks: Rainier Therapeutics
Non-financial interests: President of APRO

David J. DeGraff, PhD, Associate Editor
Nothing to Disclose

Lars Dyrskjøt, PhD, Associate Editor
Consultant: Ferring
Other Research Support: Natera, Ferring

Jason A. Efstathiou, MD, PhD, Associate Editor
Consultant: Blue Earth Diagnostics, Taris Biomedical
Scientific Advisory Board: Blue Earth Diagnostics, Janssen, Bayer Healthcare Pharmaceuticals

Bishoy M. Faltas, MD, Associate Editor
Honoraria: Springer Nature, UroToday
Clinical Trials: Eli-Lilly

Donna Hansel, MD, PhD, Associate Editor
Other Research Support: Konica Minolta
Other: Genentech, AstraZeneca, Taris

Arndt Hartmann, MD, Associate Editor
Advisory Board:AstraZeneca, BMS, Cepheid, Janssen, MSD, Qiagen, Roche
Speaker Honoraria: Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Janssen, MSD, Roche
Consultant Abbvie, 3D Histotech, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Illumina, Janssen, MSD, Nanostring, Novartis, Qiagen, Roche
Clinical Trials: Cepheid, Janssen
Other Research Support: Biotech, Cepheid, Illumina, Janssen, Nanostring, Roche

Anne Kiltie, MA, DM, DSc, Associate Editor
Other Research Support: CRUK programme grant C5255/A15935, CRUK project grant C15140/A19817

Cheryl Lee, MD, Associate Editor
Paid consultant: Merck
Board Member (non-paid): Bladder Cancer Advocacy Network

Yair Lotan, MD, Associate Editor
Scientific study or trial: Abbott, Pacific Edge, FKD, Biocancell, GenomeDx Biosciences, Inc., Photocure, MDxHealth
Consultant/advisor: Cepheid, Merck, Astra-Zeneca, Photocure, MDxHealth
Other: Urogen
Leadership position: Vessi Medical

S. Bruce Malkowicz, MD, Associate Editor
Consultant: CX Bladder
Clinical Trials: Rite –Synergo, Merck

Surena F. Matin, MD, Associate Editor
SAB: Taris Bio
Research study: QED

David McConkey, PhD, Associate Editor
Consultant: Janssen, Ranier Pharmaceuticals
Other Research Support: AstraZeneca, Ranier Pharmaceuticals

Edward M. Messing, MD, Associate Editor
Nothing to Disclose

Matt Milowsky, MD, Associate Editor
Research funding to institution: Acerta Pharma, Astellas, Bristol-Myers Squibb, Incyte, Merck, Pfizer,Roche/Genentech, Seattle Genetics, Clovis Oncology, Inc., Inovio Pharmaceuticals, AstraZeneca, X4 Pharmaceuticals
Honorarium to institution: Rainier Therapeutics (formerly BioClin), Asieris

Francisco X. Real, MD, PhD, Associate Editor
Speaker honoraria: Roche
Other Research Support: Boehringer-Ingelheim, VCN Biosciences

Bas W.G. van Rhijn, MD, PhD, Associate Editor
2017-Apr   Advisory board meeting AstraZeneca on immunotherapy diagnostics (London, UK)
2018-Dec   European Advisory board meeting Ferring on trials in NMIBC (Amsterdam, NL)

Mark S. Soloway, MD, Associate Editor
Nothing to Disclose

George Thalmann, MD, Associate Editor
Nothing to Disclose

Xue-Ru Wu, MD, Associate Editor
Nothing to Disclose

Diane Zipursky Quale, BA, JD, Associate Editor
Nothing to Disclose

Alexandre R. Zlotta, MD, PhD, Associate Editor
Consultant: AstraZeneca, Ferring, Janssen, Sanofi, Verity Pharma

Last updated: May 21, 2020